Newer Dopaminergic Agents Cause Minimal Endocrine Effects in Idiopathic Parkinson's Disease | Zendy

Jacob S. Daniel | Zendy; Jyothish Govindan | Zendy; Chandan Kamath | Zendy; C D'Souza | Zendy; Mohamed Adlan | Zendy; Lakdasa Premawardhana | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Newer Dopaminergic Agents Cause Minimal Endocrine Effects in Idiopathic Parkinson's Disease

Author(s) -

Jacob S. Daniel,

Jyothish Govindan,

Chandan Kamath,

C D'Souza,

Mohamed Adlan,

Lakdasa Premawardhana

Publication year - 2014

Publication title -

clinical medicine insights endocrinology and diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.527

H-Index - 15

ISSN - 1179-5514

DOI - 10.4137/cmed.s14902

Subject(s) - endocrine system , medicine , endocrine disease , endocrinology , dopaminergic , prolactin , luteinizing hormone , hormone , interquartile range , follicle stimulating hormone , dopamine

We studied the prevalence of endocrine dysfunction in subjects with idiopathic Parkinson's disease (IPD) on newer dopaminergic agents (DA). DA are also used in endocrine hypersecretory states in small doses and we hypothesized that endocrine dysfunction was likely in IPD where DA were used in comparatively much higher dosage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research